drugset / Trial / NCT07014917

Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL

NCT07014917

Phase 2 Recruiting 62 enrolled Zulfa Omer
RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized Phase II study of intermittent versus continuous venetoclax therapy with Acalabrutinib in previously untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Timeline

Start
2025-12-05
Primary completion
2028-06-05
Completion
2032-06-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Venetoclax Small molecule
Background Acalabrutinib Small molecule